The PacBio Sequel for Single Molecule, Real-Time, Long Read Sequencing Heguy, Adriana New York Un

The PacBio Sequel for Single Molecule, Real-Time, Long Read Sequencing
Heguy, Adriana   
New York University, New York, NY, United States

We are requesting funds to purchase a PacBio Sequel long-read, single molecule sequencer, the latest next-generation sequencing instrument, released in September of 2015. The system will be placed in the Genome Technology Center (GTC) at New York University Langone Medical Center (NYULMC), a shared resource administered by the Office of Collaborative Science and operated by experienced and highly trained staff. The GTC is under the direction of Dr. Adriana Heguy, an expert in genomics with many years of experience providing genomics research in a collaborative setting. Currently the GTC provides only short read sequences on our three HiSeqs and two MiSeqs. We have no long read single molecule capability, with the exception of a MinION which has very limited throughput and capabilities, a high error rate and is not industry-standard. The requested PacBio Sequel will be utilized to fulfill the needs of a large community of NYU investigators with established and NIH funded research programs in microbiology, metagenomics, immunology, parasite biology and basic cellular processes such as DNA methylation and DNA repair, all of which require long-read, single molecule sequencing. These projects cannot be carried out with current short-read technology and their progress has been hampered by limited access to long-read sequencing through other institutions. The PacBio Sequel is the best instrument for the needs of our investigators; it provides increased capacity and flexibility, requires less space and operates at a lower cost as compared to the previous generation PacBio RS II System. The redesigned SMRT flow cell is based on their industry- standard, proven technology for long reads, high accuracy, uniform coverage and simultaneous epigenetic characterization. The PacBio Sequel will support the NIH funded projects of 7 Major Users and 6 Minor Users at NYU. The Major Users will occupy 68% of instrument capacity; 97% capacity for combined usage of both groups. All users are NIH funded. Any remaining capacity of this instrument will be allocated for pilot projects to generate preliminary data for grant proposals. We have extensive bioinformatics and high performance computing capabilities, already enabled for PacBio data analysis and storage. NYULMC is committed to supporting cutting edge genomics through strong institutional support of the GTC, and the acquisition, implementation and maintenance of the PacBio Sequel.

Public Health Relevance

The PacBio Sequel DNA sequencer, the latest instrument from Pacific Biosciences, is the fastest, highest throughput, and most cost effective instrument for single molecule, long-read sequencing. The long reads generated by the Sequel will allow us to generate complete genomes that will contain previously hidden information about viral, parasitic, bacterial and human genomes. Access to this technology will enable biomedical investigators to answer fundamental questions regarding the nature of known and novel pathogens and their role in human disease, will likely result in the development of new targets for therapeutic intervention, and has the potential to have a major impact on human health.

我们正在申请资金购买PacBio后续长期阅读，单分子测序仪，最新的下一代测序仪器，发布于2015年9月。
该系统将被放置在纽约大学朗格尼医学中心(NYULMC)的基因组技术中心(GTC)，这是一个由合作科学办公室管理的共享资源，并由经验丰富、训练有素的工作人员操作。
GTC由Adriana Heguy博士领导，他是基因组学专家，在合作环境中提供基因组学研究有多年的经验。
目前GTC只在我们的三个HiSeqs和两个MiSeqs上提供短读序列。
我们没有长期阅读单分子的能力，除了一个MinION的吞吐量和能力非常有限，高错误率和不是工业标准。
PacBio的后续成果将被用来满足纽约大学一个大型研究团体的需求，这些研究项目包括已建立的和NIH资助的微生物学、宏基因组学、免疫学、寄生虫生物学和基本细胞过程，如DNA甲基化和DNA修复，所有这些都需要长期阅读的单分子测序。
这些项目无法用目前的短读技术进行，而且通过其他机构获得长读排序的途径有限，阻碍了这些项目的进展。
PacBio Sequel是我们研究人员需要的最佳工具;
与上一代PacBio RS II系统相比，它提供了更大的容量和灵活性，需要更少的空间，运行成本更低。
重新设计的SMRT流动池是基于他们的工业标准，成熟的技术，长读数，高精度，均匀覆盖和同步表观遗传表征。
PacBio续作将支持NIH资助的7个主要用户和6个次要用户在纽约大学的项目。
主要用户将占仪器容量的68%;
97%的能力，两者的组合使用。
所有用户都是NIH资助的。
这一文书的任何剩余能力将分配给试点项目，以便为赠款建议产生初步数据。
我们拥有广泛的生物信息学和高性能计算能力，已经能够进行PacBio数据分析和存储。
NYULMC致力于通过对GTC的强有力的制度支持，以及PacBio Sequel的收购、实施和维护来支持最前沿的基因组学。
PacBio Sequel DNA sequencer是太平洋生物科技公司的最新设备，是单分子、长读测序最快、最高通量、最具成本效益的设备。
续作生成的长序列将使我们能够生成完整的基因组，其中将包含以前隐藏的关于病毒、寄生虫、细菌和人类基因组的信息。
利用这一技术将使生物医学研究者能够回答有关已知和新病原体的性质及其在人类疾病中的作用的基本问题，很可能导致治疗干预的新目标的开发，并有可能对人类健康产生重大影响。